These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 15692974)
21. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593 [TBL] [Abstract][Full Text] [Related]
22. Rituximab for refractory polymyositis: an open-label prospective study. Mok CC; Ho LY; To CH J Rheumatol; 2007 Sep; 34(9):1864-8. PubMed ID: 17722224 [TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147 [TBL] [Abstract][Full Text] [Related]
25. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041 [TBL] [Abstract][Full Text] [Related]
26. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Arin MJ; Engert A; Krieg T; Hunzelmann N Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153 [TBL] [Abstract][Full Text] [Related]
27. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852 [TBL] [Abstract][Full Text] [Related]
29. Treatment of primary cutaneous B-cell lymphoma with rituximab. Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476 [TBL] [Abstract][Full Text] [Related]
30. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113 [TBL] [Abstract][Full Text] [Related]
31. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Popa C; Leandro MJ; Cambridge G; Edwards JC Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244 [TBL] [Abstract][Full Text] [Related]
32. [Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case]. Yáñez V J; Cisternas M M; Saldías H V; Saldías P F Rev Med Chil; 2009 Jan; 137(1):88-93. PubMed ID: 19399327 [TBL] [Abstract][Full Text] [Related]
33. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239 [TBL] [Abstract][Full Text] [Related]
34. An open study of B lymphocyte depletion in systemic lupus erythematosus. Leandro MJ; Edwards JC; Cambridge G; Ehrenstein MR; Isenberg DA Arthritis Rheum; 2002 Oct; 46(10):2673-7. PubMed ID: 12384926 [TBL] [Abstract][Full Text] [Related]
35. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. El Tal AK; Posner MR; Spigelman Z; Ahmed AR J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351 [TBL] [Abstract][Full Text] [Related]
36. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000 [TBL] [Abstract][Full Text] [Related]
37. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Goh MS; McCormack C; Dinh HV; Welsh B; Foley P; Prince HM Br J Dermatol; 2007 May; 156(5):990-6. PubMed ID: 17355229 [TBL] [Abstract][Full Text] [Related]
38. B cells in rheumatoid arthritis: from hypothesis to the clinic. Keystone EC Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii8-ii12. PubMed ID: 15851525 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221 [TBL] [Abstract][Full Text] [Related]
40. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]